Leap Investments’s Dianthus Therapeutics DNTH Stock Holding History

Leap Investments’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-788	Closed	-$79K	–	440
2020 Q1	$79K	Buy	788 +138	+21%	+$25.6K	0.12%	293
2019 Q4	$158K	Buy	+650	New	+$121K	0.07%	342

Other funds holding DNTH

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Leap Investments's DNTH Position: Q2 2020 in Review

Leap Investments sold out of Dianthus Therapeutics (DNTH) in Q2 2020, closing a stake of 788 shares — an estimated $79K sold.

Leap Investments first reported a position in DNTH in Q4 2019 and held it in 2 quarters. The position peaked at $158K in Q4 2019. 95 funds tracked by Wall St. Rank hold DNTH as of Q2 2020.

Leap Investments reported no remaining Dianthus Therapeutics position as of Q2 2020 after selling out during the quarter.
Leap Investments sold 788 Dianthus Therapeutics shares in Q2 2020, an estimated $79K.
Leap Investments first reported a position in Dianthus Therapeutics in Q4 2019 and held it in 2 quarters.
Leap Investments's Dianthus Therapeutics position peaked at $158K in Q4 2019.
95 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.